Aeglea BioTherapeutics Q3 2023 net loss $40.1M; cash $204.9M; IBD pipeline on track

Spyre Therapeutics, Inc.

2023-Q3 EPS reported -$69.57 revenue$886,000

Net loss $40.1M in Q3 2023 vs $18.2M a year ago, reflecting $24.7M R&D (+106% YoY) and $21.8M other expense.
Cash, equivalents, marketable securities and restricted cash $204.9M at Sept 30, 2023, expected runway into 2026.
SPY001 anti-α4β7 IND expected H1 2024; healthy volunteer interim data year-end 2024.
SPY002 anti-TL1A IND expected H2 2024; picomolar affinity for monomer/trimer cited.
Stockholder vote Nov 21 to authorize preferred-to-common conversion; sold pegzilarginase to Immedica for $15M upfront plus milestones.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Spyre Therapeutics, Inc. reported financial results for third quarter 2023.

Period: third quarter 2023
Result: reported results

Exact text from the filing

On November 9, 2023, Aeglea BioTherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Spyre Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001636282-23-000016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.